Biologic Agents in Psoriasis: British Association of Dermatologists' Guidelines for Biologic Intervention for Psoriasis 2009

C. H. Smith; A. V. Anstey; J. N.W.N. Barker; A. D. Burden; R. J.G. Chalmers; D. A. Chandler; A. Y. Finlay; C. E.M. Griffiths; K. Jackson; N. J. McHugh; K. E. McKenna; N. J. Reynolds; A. D. Ormerod

doi:10.1002/9781444329865.ch4

Biologic Agents in Psoriasis: British Association of Dermatologists' Guidelines for Biologic Intervention for Psoriasis 2009

C. H. Smith, A. V. Anstey, J. N.W.N. Barker, A. D. Burden, R. J.G. Chalmers, D. A. Chandler, A. Y. Finlay, C. E.M. Griffiths, K. Jackson, N. J. McHugh, K. E. McKenna, N. J. Reynolds, A. D. Ormerod

Research output: Chapter or section in a book/report/conference proceeding › Chapter or section

Abstract

Azathioprine has been available as an immunosuppressive agent for over 40 years, and current routine usage in dermatology is not restricted to licensed indications. Advances in understanding the metabolic fate of azathioprine have led to significant changes in prescribing practice and toxicity monitoring by U.K. dermatologists. The current state of knowledge concerning the use of azathioprine in dermatology is summarized, with identification of strength of evidence. Clinical indications and contraindications for azathioprine usage in dermatology are identified. Evidence-based recommendations are made for routine safety monitoring of patients treated with azathioprine, including pretreatment assessment of red blood cell thiopurine methyltransferase activity.

Original language	English
Title of host publication	British Association of Dermatologists' Management Guidelines
Editors	N. H. Cox, J. S. C. English
Publisher	Wiley-Blackwell
Pages	230-262
Number of pages	33
ISBN (Print)	9781444335521
DOIs	https://doi.org/10.1002/9781444329865.ch4
Publication status	Published - 21 Mar 2011

ASJC Scopus subject areas

General Medicine

Access to Document

10.1002/9781444329865.ch4

Cite this

Smith, C. H., Anstey, A. V., Barker, J. N. W. N., Burden, A. D., Chalmers, R. J. G., Chandler, D. A., Finlay, A. Y., Griffiths, C. E. M., Jackson, K., McHugh, N. J., McKenna, K. E., Reynolds, N. J., & Ormerod, A. D. (2011). Biologic Agents in Psoriasis: British Association of Dermatologists' Guidelines for Biologic Intervention for Psoriasis 2009. In N. H. Cox, & J. S. C. English (Eds.), British Association of Dermatologists' Management Guidelines (pp. 230-262). Wiley-Blackwell. https://doi.org/10.1002/9781444329865.ch4

Biologic Agents in Psoriasis: British Association of Dermatologists' Guidelines for Biologic Intervention for Psoriasis 2009. / Smith, C. H.; Anstey, A. V.; Barker, J. N.W.N. et al.
British Association of Dermatologists' Management Guidelines. ed. / N. H. Cox; J. S. C. English. Wiley-Blackwell, 2011. p. 230-262.

Research output: Chapter or section in a book/report/conference proceeding › Chapter or section

Smith, CH, Anstey, AV, Barker, JNWN, Burden, AD, Chalmers, RJG, Chandler, DA, Finlay, AY, Griffiths, CEM, Jackson, K, McHugh, NJ, McKenna, KE, Reynolds, NJ & Ormerod, AD 2011, Biologic Agents in Psoriasis: British Association of Dermatologists' Guidelines for Biologic Intervention for Psoriasis 2009. in NH Cox & JSC English (eds), British Association of Dermatologists' Management Guidelines. Wiley-Blackwell, pp. 230-262. https://doi.org/10.1002/9781444329865.ch4

@inbook{555b5dde92db4c04926637275dc4e164,

title = "Biologic Agents in Psoriasis: British Association of Dermatologists' Guidelines for Biologic Intervention for Psoriasis 2009",

abstract = "Azathioprine has been available as an immunosuppressive agent for over 40 years, and current routine usage in dermatology is not restricted to licensed indications. Advances in understanding the metabolic fate of azathioprine have led to significant changes in prescribing practice and toxicity monitoring by U.K. dermatologists. The current state of knowledge concerning the use of azathioprine in dermatology is summarized, with identification of strength of evidence. Clinical indications and contraindications for azathioprine usage in dermatology are identified. Evidence-based recommendations are made for routine safety monitoring of patients treated with azathioprine, including pretreatment assessment of red blood cell thiopurine methyltransferase activity.",

author = "Smith, {C. H.} and Anstey, {A. V.} and Barker, {J. N.W.N.} and Burden, {A. D.} and Chalmers, {R. J.G.} and Chandler, {D. A.} and Finlay, {A. Y.} and Griffiths, {C. E.M.} and K. Jackson and McHugh, {N. J.} and McKenna, {K. E.} and Reynolds, {N. J.} and Ormerod, {A. D.}",

year = "2011",

month = mar,

day = "21",

doi = "10.1002/9781444329865.ch4",

language = "English",

isbn = "9781444335521",

pages = "230--262",

editor = "Cox, {N. H.} and English, {J. S. C.}",

booktitle = "British Association of Dermatologists' Management Guidelines",

publisher = "Wiley-Blackwell",

address = "USA United States",

}

TY - CHAP

T1 - Biologic Agents in Psoriasis

T2 - British Association of Dermatologists' Guidelines for Biologic Intervention for Psoriasis 2009

AU - Smith, C. H.

AU - Anstey, A. V.

AU - Barker, J. N.W.N.

AU - Burden, A. D.

AU - Chalmers, R. J.G.

AU - Chandler, D. A.

AU - Finlay, A. Y.

AU - Griffiths, C. E.M.

AU - Jackson, K.

AU - McHugh, N. J.

AU - McKenna, K. E.

AU - Reynolds, N. J.

AU - Ormerod, A. D.

PY - 2011/3/21

Y1 - 2011/3/21

N2 - Azathioprine has been available as an immunosuppressive agent for over 40 years, and current routine usage in dermatology is not restricted to licensed indications. Advances in understanding the metabolic fate of azathioprine have led to significant changes in prescribing practice and toxicity monitoring by U.K. dermatologists. The current state of knowledge concerning the use of azathioprine in dermatology is summarized, with identification of strength of evidence. Clinical indications and contraindications for azathioprine usage in dermatology are identified. Evidence-based recommendations are made for routine safety monitoring of patients treated with azathioprine, including pretreatment assessment of red blood cell thiopurine methyltransferase activity.

AB - Azathioprine has been available as an immunosuppressive agent for over 40 years, and current routine usage in dermatology is not restricted to licensed indications. Advances in understanding the metabolic fate of azathioprine have led to significant changes in prescribing practice and toxicity monitoring by U.K. dermatologists. The current state of knowledge concerning the use of azathioprine in dermatology is summarized, with identification of strength of evidence. Clinical indications and contraindications for azathioprine usage in dermatology are identified. Evidence-based recommendations are made for routine safety monitoring of patients treated with azathioprine, including pretreatment assessment of red blood cell thiopurine methyltransferase activity.

UR - http://www.scopus.com/inward/record.url?scp=84888704023&partnerID=8YFLogxK

U2 - 10.1002/9781444329865.ch4

DO - 10.1002/9781444329865.ch4

M3 - Chapter or section

AN - SCOPUS:84888704023

SN - 9781444335521

SP - 230

EP - 262

BT - British Association of Dermatologists' Management Guidelines

A2 - Cox, N. H.

A2 - English, J. S. C.

PB - Wiley-Blackwell

ER -

Biologic Agents in Psoriasis: British Association of Dermatologists' Guidelines for Biologic Intervention for Psoriasis 2009

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this